Literature DB >> 16460351

Immune complex-based vaccine for pig protection against parvovirus.

B Roić1, S Cajavec, N Ergotić, Z Lipej, J Madić, M Lojkić, B Pokrić.   

Abstract

The insoluble immune complexes (ICs) were prepared under the conditions of double immunodiffusion in gel, using the suspension of the ultrasound treated PK-15 cell-line infected with porcine parvovirus (PPV) containing both viral particles and viral proteins, as well as pig or rabbit anti-PPV polyclonal immune sera. The immunodiffusion performed in an agarose gel allows only viral subunits with a molecular mass equal to or less than 1000 kDa, rather than the viral particles, to diffuse through the gel and reach the point where the immunoprecipitate is to be formed. The immunoprecipitation under the conditions of the diffusion ensures the optimal, i.e. equimolar ratio of both immunoprecipitating components, antibody/antigen in the IC. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the Western blot analyses showed the ICs were composed of two proteins, a protein in which molecular mass corresponded to the VP2 of the PPV and a protein with a molecular mass of the IgG. This suggests that the ICs are mainly composed of the VP2 antigen and IgG class antibodies. The potency of the IC-vaccines prepared in the form of a water-in-oil-in-water emulsion was compared with that of a commercially available, inactivated oil vaccine. The vaccination of gilts, 6 weeks before mating, with the IC containing allogeneic pig antibodies, resulted in the development of high and long-lasting anti-PPV antibody titres, similar to those generated by the licenced vaccine (P > 0.01). The content of the virus material administered by the IC was twice lower than that in the licenced vaccine. Neither systemic nor local reactions were observed in the gilts during the period of the trial with the IC vaccine. The number of viable piglets per litter varied between 9 and 12 and no signs of the PPV infection were detected. Rabbits were used as one of the alternative laboratory animal models accepted for the testing of the vaccine against the PPV. The rabbit humoral immune response generated by the IC containing the allogeneic antibodies were higher than that generated by the ICs containing the xenogeneic pig antibodies. It was similar to that generated by two-times higher content of the virus material administered by a commercially available vaccine. The IC-based vaccines belong to non-replicating, subunit vaccines, which are both ecologically convenient and the safest vaccines of all.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16460351     DOI: 10.1111/j.1439-0450.2006.00907.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  7 in total

1.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

2.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

3.  Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Authors:  Rajnish Kumar; Michael Tuen; Jianping Liu; Arthur Nàdas; Ruimin Pan; Xiangpeng Kong; Catarina E Hioe
Journal:  Vaccine       Date:  2013-09-16       Impact factor: 3.641

4.  Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.

Authors:  Rajnish Kumar; Maria Luisa Visciano; Hualin Li; Catarina Hioe
Journal:  J AIDS Clin Res       Date:  2012-03-09

5.  The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

Authors:  Catarina E Hioe; Maria Luisa Visciano; Rajnish Kumar; Jianping Liu; Ethan A Mack; Rachel E Simon; David N Levy; Michael Tuen
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 6.  Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases.

Authors:  Alex F Tang; Gospel Enyindah-Asonye; Catarina E Hioe
Journal:  Vaccines (Basel)       Date:  2021-02-02

7.  Host- and pathogen-derived adjuvant coatings on protein nanoparticle vaccines.

Authors:  Timothy Z Chang; Ishatou Diambou; Jong Rok Kim; Baozhong Wang; Julie A Champion
Journal:  Bioeng Transl Med       Date:  2017-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.